Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients. LeBlanc, FR; Breese, EH; Burns, KC; Chang, EK; Jones, LQ M; Lee, L; Mizukawa, B; Norris, RE; O'Brien, MM; Phillips, CL; Perentesis, JP; Rubinstein, J; Pommert, L. British Journal of Haematology. 2024; 205:1055-1066.

SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation. Chang, YH; Yamamoto, K; Fujino, T; Wang, TW; Sugimoto, E; Zhang, W; Yabushita, T; Suzaki, K; Pietsch, EC; Weir, BA; Enomoto, Y; Imai, Y; Kitamura, T; Goyama, S. Cell Reports. 2024; 43:114536.

P676: UPDATED RESULTS FROM THE TRIAL ITCC‐054/COG‐AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA. Brivio, E; Pennesi, E; Willemse, M; Jiang, Y; van der Velden, V; Beverloo, B; Hudson, C; Kuttschreuter, L; van der Sluis, I; Brethon, B; Locatelli, F; Roth, M; Hijiya, N; Zwaan, M. HemaSphere. 2023; 7:e506783a.

The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Rubinstein, JD; Breese, EH; Krupski, MC; O'Brien, MM; Dandoy, CE; Mizukawa, B; Khoury, R; Norris, RE; Davies, SM; Phillips, CL. Transplantation and Cellular Therapy. 2023; 29:311.e1-311.e7.

Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy. Bender, JD; Rubinstein, JD; Mizukawa, B; Perentesis, JP; Pommert, L. Pediatric Blood and Cancer. 2023; 70:e30214.

IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia. Liu, X; Sato, N; Yabushita, T; Li, J; Jia, Y; Tamura, M; Asada, S; Fujino, T; Fukushima, T; Yonezawa, T; Shibata, T; Miyake, K; Kitamura, T; Goyama, S. EMBO Molecular Medicine. 2023; 15:e15631.

Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis. Nayak, RC; Chang, KH; Singh, AK; Kotliar, M; Desai, M; Wellendorf, AM; Wunderlich, M; Bartram, J; Mizukawa, B; Cuadrado, M; Dexheimer, P; Barski, A; Bustelo, XR; Nassar, NN; Cancelas, JA. Nature Communications. 2022; 13:3056.

Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. Hegde, S; Gasilina, A; Wunderlich, M; Lin, Y; Buchholzer, M; Krumbach, OH F; Akbarzadeh, M; Ahmadian, MR; Seibel, W; Zheng, Y; Perentesis, JP; Mizukawa, BE; Vinnedge, LP; Cancelas, JA; Nassar, NN. Leukemia. 2022; 36:637-647.

PDX models of relapsed pediatric AML preserve global gene expression patterns and reveal therapeutic targets. Wunderlich, M; Chen, J; Sexton, C; Manning, N; Byerly, L; O’Brien, E; Perentesis, J; Mulloy, J; Mizukawa, B. 2022; 2022.01.31.478534.

Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. Sabnis, HS; Shulman, DS; Mizukawa, B; Bouvier, N; Zehir, A; Fangusaro, J; Fabrizio, VA; Whitlow, C; Winchester, M; Agresta, L; DuBois, SG; Glade-Bender, J; Castellino, SM; Shukla, N. Journal of Clinical Oncology. 2021; 39:3822-3828.